Bremelanotide (PT-141) significantly improved desire scores on a newly validated questionnaire for premenopausal HSDD
Background
Effective measurement of sexual desire is critical for evaluating treatments for hypoactive sexual desire disorder (HSDD), a common condition in premenopausal women. Existing patient-reported outcome (PRO) measures may not fully capture the nuances of desire. To address this, the Elements of Desire Questionnaire (EDQ) was developed based on literature reviews, patient interviews, and expert input. It was designed specifically to provide a more detailed assessment of sexual desire in clinical trials for HSDD. This study's objective was to rigorously evaluate the measurement properties—reliability, validity, and sensitivity to change—of the EDQ within the context of two large-scale Phase 3 clinical trials.
Study Design
This study analyzed data from two identically designed Phase 3 trials (RECONNECT) involving premenopausal women with HSDD. Participants completed a daily version of the EDQ for 7 consecutive days before select monthly clinic visits and a monthly recall version at each visit. The analysis included 1144 subjects who completed the monthly EDQ and 676 who completed the daily EDQ at baseline. The study evaluated the EDQ's psychometric properties and its ability to detect changes in desire following treatment with bremelanotide versus placebo over a 6-month period.
Results
The Elements of Desire Questionnaire (EDQ) demonstrated strong psychometric properties. Both the monthly and daily recall versions showed good internal consistency and test-retest reliability. The EDQ scores were significantly correlated with the desire domain scores of the established Female Sexual Function Index (FSFI), confirming the EDQ's validity in measuring sexual desire. Crucially, the questionnaire was sensitive to treatment effects.
After 6 months of treatment, participants receiving bremelanotide showed a significantly greater improvement in sexual desire compared to the placebo group, as measured by both the monthly and daily recall versions of the EDQ (both P < 0.0001). This indicates that the EDQ can effectively detect clinically meaningful changes in desire resulting from an intervention.
Key Findings
- After 6 months, bremelanotide treatment led to significantly greater improvement in EDQ scores versus placebo (P < 0.0001).
- The analysis population included 1144 subjects for the monthly EDQ and 676 for the daily EDQ at baseline.
- The EDQ (both monthly and daily versions) demonstrated good internal consistency and test-retest reliability.
- EDQ scores were well-correlated with the desire domain scores of the Female Sexual Function Index (FSFI).
Why It Matters
This validation provides a new, reliable tool for both researchers and clinicians to more accurately measure sexual desire in women with HSDD. For individuals using or considering peptides like bremelanotide, the EDQ offers a more nuanced way to track subjective improvements beyond simple event counts. The strong performance of the EDQ in these Phase 3 trials supports its use as a primary or secondary endpoint in future studies of HSDD treatments, potentially accelerating the development of new therapies. This robust validation strengthens the evidence for bremelanotide's efficacy by demonstrating its positive impact on a specific, patient-centered measure of desire. This moves the assessment of sexual function beyond older metrics and towards a more holistic understanding of the patient experience.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
